Marché Fermé -
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
23,3 NOK | -2,51 % | -3,72 % | 0,00 % |
24/04 | Vistin Pharma ASA publie ses résultats pour le premier trimestre clos le 31 mars 2024 | CI |
24/04 | Transcript : Vistin Pharma ASA, Q1 2024 Earnings Call, Apr 24, 2024 |
Métier
Nombre d'employés: 78
Ventes par activité
NOK en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Pharmaceuticals
100,0
%
| 288 | 100,0 % | 435 | 100,0 % | +51,35 % |
Ventes par région
NOK en Millions | 2022 | Poids | 2023 | Poids | Delta |
---|---|---|---|---|---|
Europe
77,8
%
| 196 | 68,1 % | 339 | 77,8 % | +72,91 % |
Africa
15,1
%
| 37 | 13,0 % | 66 | 15,1 % | +75,29 % |
Asia
6,7
%
| 20 | 6,9 % | 29 | 6,7 % | +48,11 % |
North and South America
0,3
%
| 34 | 12,0 % | 2 | 0,3 % | -95,63 % |
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Chief Executive Officer | - | 01/03/20 | |
Director of Finance/CFO | - | 02/03/20 | |
Eivind Egeli
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/15 |
Vegard Heggem
PRN | Corporate Officer/Principal | - | 01/06/15 |
Sabrina Berge
PRN | Corporate Officer/Principal | - | 01/06/15 |
General Counsel | - | 01/03/15 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Chairman | 76 | 01/06/20 | |
Director/Board Member | 62 | 06/03/15 | |
Director/Board Member | 60 | - | |
Bettina Banoun
BRD | Director/Board Member | 52 | 08/05/18 |
Åse Musum
BRD | Director/Board Member | - | 01/06/15 |
Director/Board Member | - | 04/05/20 | |
Director/Board Member | - | 01/01/17 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 44 344 592 | 20 062 899 ( 45,24 %) | 0 | 45,24 % |
Coordonnées société
Sociétés du groupe
Nom | Catégorie et Secteur |
---|---|
Vistin Trading AS
Vistin Trading AS Finance/Rental/LeasingFinance Part of Vistin Pharma ASA, Vistin Trading AS offers trade in financial instruments and other investments. The private company is based in Oslo, Norway. |
Finance/Rental/Leasing
|
Vistin Pharma AS
Vistin Pharma AS Pharmaceuticals: MajorHealth Technology Part of Vistin Pharma ASA, Vistin Pharma is a leading European metformin producer supplying to international pharmaceutical companies. The private company is located in Norway. Metformin is a standard first-line treatment for type 2 diabetes. The Norwegian company believes in balancing business growth with environmental sustainability, social responsibility, and ethical business practices. |
Pharmaceuticals: Major
|
Secteur
Ventes par région
Varia. 1 janv. | Capi. | |
---|---|---|
0,00 % | 95,97 M | |
+20,91 % | 43,34 Md | |
+20,91 % | 21,96 Md | |
+13,30 % | 14,09 Md | |
+13,30 % | 13,64 Md | |
+39,38 % | 11,43 Md | |
-9,62 % | 6,86 Md | |
-0,05 % | 6,79 Md | |
-8,87 % | 5,73 Md | |
+9,64 % | 5,22 Md |
- Bourse
- Actions
- Action VISTN
- Société Vistin Pharma ASA